Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.44 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.44 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.44 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14709694 | 0.94 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL14709476 | 0.93 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL14709389 | 0.93 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL14709599 | 0.92 | GUCY1B2 (0.42) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL14709570 | 0.92 | GUCY1B2 (0.44) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL14709566 | 0.92 | GUCY1B2 (0.44) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL14709583 | 0.92 | CD274 (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL14709577 | 0.90 | GUCY1B2 (0.52) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15164331 | 0.90 | GUCY1B2 (0.42) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL19111671 | 0.90 | GUCY1B2 (0.43) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766360-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INT (DE) | 2017-07-12 | — | — | EP | disclosed |
| US-8815857-B2 | Soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-8815857-B2 | Soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20130203729-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203729-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | US | disclosed |
| WO-2013025425-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203729-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, GUCY1B1 | GUCY1B2 4/4885GUCY1A2 1/4885GUCY1A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.